natgillin/translations-raw huggingface dataset:
Copalia is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely.
Copalia se ne preporučuje majkama koje doje, a ako želite dojiti liječnik Vam može odabrati drugo liječenje, posebno ako je Vaše dijete novorođenče ili je prijevremeno rođeno.
Copalia must not be used in patients who are hypersensitive (allergic) to amlodipine or other medicines in the ‘dihydropyridine derivatives’ class, to valsartan, or to any of the other ingredients.
Copalia se ne smije primjenjivati u bolesnika koji su preosjetljivi (alergični) na amlodipin ili druge lijekove iz klase „derivati dihidropiridina”, na valsartan ili bilo koju drugu pomoćnu tvar.
Copalia should be discontinued immediately in patients who develop angioedema and should not be re-administered.
Bolesnici u kojih se razvije angioedem trebaju odmah prekinuti primjenu Copalie i više je ne smiju ponovo uzimati.
COPD exacerbation data was collected in the 6- and 12–month pivotal studies.
Podaci o egzacerbaciji KOPB-a prikupljeni su iz 6- i 12-mjesečnih ključnih ipitivanja.
COPD exacerbations
Egzacerbacije KOPB-a
COPD flare-ups were reduced by between 13 and 34% in those using Relvar Ellipta compared with vilanterol alone.
Pogoršanja KOPB-a su smanjena za 13 do 34% u bolesnika koji su koristili Relvar Ellipta u usporedbi s monoterapijom vilanterolom.
COPD flare-ups were reduced by between 13 and 34% in those using Revinty Ellipta compared with vilanterol alone.
Pogoršanja KOPB-a smanjena su za 13 do 34% u bolesnika koji su koristili lijek Revinty Ellipta u usporedbi s monoterapijom vilanterolom.
COPD is a long- term condition in which the airways and air-sacs in the lungs gradually become blocked or damaged, leading to breathing difficulties that slowly get worse.
KOPB je dugotrajna bolest kod koje dolazi do postupne blokade ili oštećenja dišnih putova i zračnih mjehurića (alveola) u plućima, što uzrokuje tegobe s disanjem koje se polako pogoršavaju.
COPD is a long-term disease and you should use this medicine every day and not only when you have breathing problems or other symptoms of COPD.
KOPB je dugoročna bolest i trebate primijeniti ovaj lijek svaki dan, a ne samo kada imate poteškoće s disanjem ili druge simptome KOPB-a.
COPD is a long-term disease in which the airways and air sacs inside the lungs become damaged or blocked, leading to difficulty breathing.
KOPB je dugotrajna bolest kod koje su dišni putovi i zračne vrećice u plućima oštećeni ili začepljeni, što dovodi do poteškoća u disanju.
COPD is a long-term disease in which the airways and air sacs inside the lungs become damaged or blocked, leading to difficulty breathing.
KOPD je dugoročna bolest pri kojoj dolazi do oštećenja ili začepljenja zračnih putova i zračnih vrećica unutar pluća, što uzrokuje poteškoće s disanjem.
COPD is a long-term disease in which the airways and air sacs inside the lungs become damaged or blocked, leading to difficulty in breathing.
KOPB je dugotrajna bolest tijekom koje dolazi do oštećenja ili blokiranja zračnih putova i zračnih vrećica unutar pluća, što uzrokuje poteškoće u disanju.
COPD is a long-term disease; therefore, Brimica Genuair must be used every day, twice a day and not only when breathing problems or other symptoms of COPD are experienced.
KOPB je dugotrajna bolest; stoga se Brimica Genuair mora koristiti svakodnevno, dvaput na dan, a ne samo kad imate probleme s disanjem ili druge simptome KOPB-a.
COPD is a long-term disease; therefore, Duaklir Genuair must be used every day, twice a day and not only when breathing problems or other symptoms of COPD are experienced.
KOPB je dugotrajna bolest; stoga se Duaklir Genuair mora koristiti svakodnevno, dvaput na dan, a ne samo kad imate probleme s disanjem ili druge simptome KOPB-a.
COPD is a long-term disease; therefore, it is recommended that Bretaris Genuair is used every day, twice a day and not only when breathing problems or other symptoms of COPD are experienced.
KOPB je dugotrajna bolest; stoga se preporučuje koristiti Bretaris Genuair svakodnevno, dvaput na dan, a ne samo kad imate probleme s disanjem ili druge simptome KOPB-a.
COPD is a long-term disease; therefore, it is recommended that Eklira Genuair is used every day, twice a day and not only when breathing problems or other symptoms of COPD are experienced.
KOPB je dugotrajna bolest; stoga se preporučuje koristiti Eklira Genuair svakodnevno, dvaput na dan, a ne samo kad imate probleme s disanjem ili druge simptome KOPB-a.
COPD is a long-term lung disease of the airways in the lungs, which is often caused by cigarette smoking.
KOPB je dugotrajna plućna bolest dišnih puteva u plućima koja je često uzrokovana pušenjem cigareta.
COPD medicinal products
Lijekovi za KOPB
copies >/= 25,614
>/= 25614
Copies of the patient card to be given to patients before they receive Ruconest
primjerke kartice za bolesnika koji će se bolesnicima dati prije nego što prime Ruconest
Copies of the patient card to be given to patients or caregivers before they receive Daxas
Kopije kartice za bolesnike za uručiti bolesnicima prije nego dobiju Daxas
Copies of the patient card to be given to patients or caregivers before they receive Libertek
Kopije kartice za bolesnike za uručiti bolesnicima prije nego dobiju Libertek
copies/ml)a
kopija/ml)a
copies/ml)§#
kopija/ml)§#
copolymer/Alu/EAA
kopolimer/Alu/EAA
copolymer/PE)
kopolimer/PE)
Copovidone Sorbitan laurate
Kopovidon Sorbitanlaurat
Coppell et al in 2010 reported data from a large meta-analysis of 235 patients with severe VOD showing a background mortality rate of severe VOD of 84.3% and that this mortality rate has remained constant over several decades.
Coppell i suradnici zabilježili su 2010. podatke iz velike metaanalize provedene na 235 bolesnika s teškom veno-okluzivnom bolešću, koji su pokazali osnovnu stopu smrtnosti zbog teške veno- okluzivne bolesti od 84,3% te da je ta stopa smrtnosti ostala konstantna tijekom nekoliko desetljeća.
Copper-64 decays by an emission of β+ (17.6 %) with a maximum energy of 0.66 MeV, an emission of β- (38.5 %) with a maximum energy of 0.58 MeV and electronic capture (43.9 %).
Bakar-64 se raspada emisijom β+ čestica (17,6%), uz maksimalnu energiju od 0,66 MeV, emisijom β- čestica (38,5%), uz maksimalnu energiju od 0,58 MeV i elektronskim uhvatom (43,9%).
Copper-64 decays in stable Nickel 64Ni (61 %) by an emission of β+ (18 %) or by an electronic capture (43 %).
Bakar-64 se raspada u stabilni nikal 64Ni (61%) emisijom β+ čestica (18%) ili elektronskim uhvatom (43%).
Copy of the Summary of Product Characteristics (SPC)
Primjerak sažetka opisa svojstava lijeka (SPC)
Corbilta 100 mg/25 mg/200 mg film-coated tablets
Corbilta 100 mg/25 mg/200 mg filmom obložene tablete
Corbilta 100 mg/25 mg/200 mg film-coated tablets levodopa/carbidopa/entacapone
Corbilta 100 mg/25 mg/200 mg filmom obložene tablete levodopa/karbidopa/entakapon
Corbilta 100 mg/25 mg/200 mg: brownish or greyish red, oval, unscored film-coated tablets marked with ‘LCE 100’ on one side.
Corbilta 100 mg/25 mg/200 mg: smećkasto ili sivkasto-crvene, ovalne filmom obložene tablete, bez ureza, s oznakom "LCE 100" na jednoj strani.
Corbilta 125 mg/31.25 mg/200 mg film-coated tablets
Corbilta 125 mg/31,25 mg/200 mg filmom obložene tablete
Corbilta 125 mg/31.25 mg/200 mg film-coated tablets levodopa/carbidopa/entacapone
Corbilta 125 mg/31,25 mg/200 mg filmom obložene tablete levodopa/karbidopa/entakapon
Corbilta 125 mg/31.25 mg/200 mg: light brownish red, oval film-coated tablets marked with ‘LCE 125’ on one side.
Corbilta 125 mg/31,25 mg/200 mg: svijetlo smećkasto-crvene, ovalne filmom obložene tablete, s oznakom "LCE 125" na jednoj strani.
Corbilta 150 mg/37.5 mg/200 mg film-coated tablets
Corbilta 150 mg/37,5 mg/200 mg filmom obložene tablete
Corbilta 150 mg/37.5 mg/200 mg film-coated tablets levodopa/carbidopa/entacapone
Corbilta 150 mg/37,5 mg/200 mg filmom obložene tablete levodopa/karbidopa/entakapon
Corbilta 150 mg/37.5 mg/200 mg: brownish or greyish red, elongated-ellipse shaped, unscored film- coated tablets marked with ‘LCE 150’ on one side.
Corbilta 150 mg/37,5 mg/200 mg: smećkasto- ili sivkasto-crvene, izdužene filmom obložene tablete u obliku elipse, bez ureza, s oznakom "LCE 150" na jednoj strani.
Corbilta 175 mg/43.75 mg/200 mg film-coated tablets
Corbilta 175 mg/43,75 mg/200 mg filmom obložene tablete
Corbilta 175 mg/43.75 mg/200 mg film-coated tablets levodopa/carbidopa/entacapone
Corbilta 175 mg/43,75 mg/200 mg filmom obložene tablete levodopa/karbidopa/entakapon
Corbilta 175 mg/43.75 mg/200 mg: light brownish red, oval, unscored film-coated tablets marked with ‘LCE 175’ on one side.
Corbilta 175 mg/43,75 mg/200 mg: svijetlo smećkasto-crvene, ovalne filmom obložene tablete, bez razdjelnog ureza, s oznakom ‘LCE 175’ na jednoj strani.
Corbilta 200 mg/50 mg/200 mg film-coated tablets
Corbilta 200 mg/50 mg/200 mg filmom obložene tablete
Corbilta 200 mg/50 mg/200 mg film-coated tablets levodopa/carbidopa/entacapone
Corbilta 200 mg/50 mg/200 mg filmom obložene tablete levodopa/karbidopa/entakapon
Corbilta 200 mg/50 mg/200 mg: dark brownish red, oval, unscored film-coated tablets marked with ‘LCE 200’ on one side.
Corbilta 200 mg/50 mg/200 mg: tamno smećkasto-crvene, ovalne filmom obložene tablete, bez ureza, s oznakom "LCE 200" na jednoj strani.
Corbilta 50 mg/12.5 mg/200 mg film-coated tablets
Corbilta 50 mg/12,5 mg/200 mg filmom obložene tablete
Corbilta 50 mg/12.5 mg/200 mg film-coated tablets levodopa/carbidopa/entacapone
Corbilta 50 mg/12,5 mg/200 mg filmom obložene tablete levodopa/karbidopa/entakapon
Corbilta 50 mg/12.5 mg/200 mg: brownish or greyish red, round, convex unscored film-coated tablets marked with ‘LCE 50’ on one side.
Corbilta 50 mg/12,5 mg/200 mg: smećkasto ili sivkasto-crvene, okrugle, konveksne filmom obložene tablete, bez ureza, s oznakom "LCE 50" na jednoj strani.
Corbilta 75 mg/18.75 mg/200 mg film-coated tablets
Corbilta 75 mg/18,75 mg/200 mg filmom obložene tablete
Corbilta 75 mg/18.75 mg/200 mg: light brownish red, oval film-coated tablets marked with ‘LCE 75’ on one side.
Corbilta 75 mg/18,75 mg/200 mg: svijetlo smećkasto-crvene, ovalne filmom obložene tablete, s oznakom "LCE 75" na jednoj strani.
Corbilta contains sucrose, and therefore patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
Corbilta sadržava saharozu te stoga bolesnici s rijetkim nasljednim problemima nepodnošenja fruktoze, malapsorpcije glukoze-galaktoze ili nedostatka saharaza-izomaltaze ne bi smjeli uzimati ovaj lijek.
Corbilta is available as a range of tablets in seven strengths, containing 50 to 200 mg levodopa and to 50 mg carbidopa.
Corbilta dostupan je u rasponu tableta u sedam jakosti koje sadrže 50 do 200 mg levodope i 12,5 do 50 mg karbidope.
Corbilta is indicated for the treatment of adult patients with Parkinson’s disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (DDC) inhibitor treatment.
Corbilta je indicirana za liječenje odraslih bolesnika s Parkinsonovom bolešću, kao i za liječenje motoričkih fluktuacija na kraju intervala doziranja koje nisu stabilizirane primjenom levodope/ inhibitora dopa dekarboksilaze (DDC).
Corbilta is indicated for the treatment of adult patients with Parkinson’s disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (DDC) inhibitor treatment.
Corbilta je indicirana za liječenje odraslih bolesnika s Parkinsonovom bolešću, kao i za liječenje motoričkih fluktuacija na kraju intervala doziranja koje nisu stabilizirane primjenom levodope/inhibitora dopa dekarboksilaze (DDC).
Corbilta is not recommended for the treatment of drug-induced extrapyramidal reactions
Corbilta se ne preporučuje za liječenje ekstrapiramidnih reakcija izazvanih lijekovima.
Corbilta is used for the treatment of Parkinson’s disease.
Corbilta se koristi za liječenje Parkinsonove bolesti.
Corbilta is used in patients who are being treated with a combination of levodopa and an inhibitor of dopa decarboxylase (two standard treatments for Parkinson’s disease) but are having ‘fluctuations’ towards the end of the period between two doses of their medication.
Corbilta koristi se u bolesnika koji se liječe kombinacijom levodope i inhibitora dopa dekarboksilaze (dvije standardne terapije za Parkinsonovu bolest), ali imaju „fluktuacije” prema kraju razdoblja između dvije doze lijeka.
Corbilta may be taken with or without food.
Corbilta se može uzeti sa ili bez hrane.
Corbilta may induce orthostatic hypotension.
Corbilta može izazvati ortostatsku hipotenziju.
Corbilta must not be used together with other medicines that belong to the group ‘monoamine oxidase inhibitors’ (a type of antidepressant).
Corbilta ne smije se koristiti skupa s drugom lijekovima koji pripadaju skupini „inhibitora monoamino oksidaze” (vrsta antidepresiva).
Corbilta therapy should be administered cautiously to patients with ischemic heart disease, severe cardiovascular or pulmonary disease, bronchial asthma, renal or endocrine disease, history of peptic ulcer disease or history of convulsions.
Liječenje Corbiltom treba provoditi uz oprez u bolesnika s ishemijskom bolešću srca, teškom kardiovaskularnom ili plućnom bolešću, bronhijalnom astmom, bubrežnom ili endokrinom bolešću, kao i u bolesnika s peptičkim ulkusom ili konvulzijama u anamnezi.
Core radiology assessment was discontinued after the primary endpoint had been met.
Nakon što je postignuta primarna mjera ishoda, osnovna radiološka procjena je prekinuta.
Core:
Jezgra :
Core: lactose monohydrate, maize starch, povidone (K90), magnesium stearate,
Jezgra: laktoza hidrat, kukuruzni škrob, povidon (K90), magnezijev stearat.
Core: sodium carbonate (anhydrous), mannitol, crospovidone, povidone K90, calcium stearate.
Jezgra: natrijev karbonat (bezvodni), manitol, krospovidon, povidon K90, kalcijev stearat.
Corifollitropin alfa exposure after a single subcutaneous injection is 665 hours*ng/mL (AUC, 426-1,037 hours*ng/mL1) and is similar after administration of 100 micrograms corifollitropin alfa to women with a body weight less than or equal to 60 kilograms and of 150 micrograms corifollitropin alfa to women with a body weight greater than 60 kilograms.
Izloženost korifolitropinu alfa nakon jedne supkutane injekcije traje 665 sati*ng/ml (AUC, 426-1037 sati*ng/ml1) i slična je u žena tjelesne težine jednake ili manje od 60 kilograma nakon primjene 100 mikrograma korifolitropina alfa i u žena tjelesne težine veće od 60 kilograma nakon primjene 150 mikrograma korifolitropina alfa.
Corifollitropin alfa has an elimination half-life of 70 hours (59-82 hours1) and a clearance of 0.13 L/h (0.10-0.18 L/h1).
Poluvrijeme eliminacije korifolitropina alfa iznosi 70 sati (59-82 sata1), a klirens je 0,13 l/h (0,10-0,18 l/h1).
Corifollitropin alfa is produced by a method known as ‘recombinant DNA technology’.
Korifolitropin alfa proizveden je metodom poznatom pod nazivom „tehnologija rekombinantne DNK”.
Cork Road Waterford Ireland
Cork Road Waterford Irska
Cork Road Waterford Republic of Ireland
Cork Road Waterford Republika Irska
Corlentor has also been compared with placebo in one main study involving 6,558 patients with long- term moderate to severe heart failure.
Corlentor je također uspoređen s placebom u jednom glavnom ispitivanju koje je uključivalo 6.558 bolesnika s kroničnim umjerenim do ozbiljnim zatajenjem srca.
Corlentor has been studied in five main studies involving over 4,000 adults with long-term stable angina.
Corlentor se ispitivao u pet glavnih ispitivanja koja su obuhvatila više od 4 000 odraslih osoba s kroničnom stabilnom anginom.
Corlentor is a medicine that contains the active substance ivabradine.
Corlentor je lijek koji sadrži djelatnu tvar ivabradin.
Corlentor is also used in patients with long-term heart failure (when the heart cannot pump enough blood to the rest of the body) who have a normal heart rhythm but whose heart rate is at least 75 beats per minute.
Corlentor se također primjenjuje u bolesnika s kroničnim zatajenjem srca (kada srce ne može opskrbljivati ostatak tijela s dovoljno krvi), koji imaju normalni srčani ritam, no čija je srčana frekvencija najmanje 75 otkucaja po minuti.
Corlentor is used to treat the symptoms of long-term stable angina (pains to the chest, jaw and back, brought on by physical effort) in adults with coronary artery disease (disease of the heart caused by the obstruction of the blood vessels that supply blood to the heart muscle) who have a normal heart rhythm.
Corlentor se koristi za simptomatsko liječenje kronične stabilne angine (boli u prsima, čeljusti i leđima, koja je uzrokovana fizičkim naporom) u odraslih osoba s koronarnom arterijskom bolesti (bolesti srca koju uzrokuje opstrukcija krvnih žila koje opskrbljuju srčani mišić krvlju) s normalnim srčanim ritmom.
Corlentor ivabradine
Corlentor ivabradin
Corlentor must not be used in patients who have a resting heart rate below 70 beats per minute, very low blood pressure, various types of heart disorder (including cardiogenic shock, rhythm disorders, heart attack, unstable or acute (sudden) heart failure and unstable angina) or severe liver problems.
Corlentor se ne smije koristiti u bolesnika koji imaju srčanu frekvenciju u mirovanju manju od 60 otkucaja po minuti, vrlo niski krvni tlak, različite tipove srčanog poremećaja (uključujući kardiogeni šok, poremećaj ritma, infarkt miokarda, nestabilno ili akutno (iznenadno) zatajenje srca i nestabilnu anginu) ili ozbiljne probleme s jetrom.
Corlentor was also more effective than placebo when added to atenolol.
Corlentor je bio djelotvorniji od placeba ako se dodao atenololu.
Corneal diseases
Poremećaji rožnice
Corneal disorders are a known adverse reaction with Teysuno use.
Poremećaji rožnice poznata su nuspojava kod primjene lijeka Teysuno.
Corneal epithelia atrophy and corneal translucencies
Atrofija epitela rožnice i prozirnost rožnice
Corneal epithelium defect,
defekt epitela rožnice,
Corneal erosion (mild or moderate) Corneal epithelium disorder Corneal oedema
Erozija rožnice (blaga ili umjerena) Poremećaj epitela rožnice
corneal erosion, corneal epithelium defect, corneal epithelium disorder, punctate keratitis, keratitis, corneal staining, eye discharge, photophobia, vision blurred, visual acuity reduced, blepharospasm, ocular discomfort, eye pruritus, conjunctival follicles, conjunctival disorder, foreign body sensation in eyes, lacrimation increased, erythema of eyelid, eyelid oedema, eyelid disorder, ocular hyperaemia
erozija rožnice, defekt rožničnog epitela, poremećaj epitela rožnice, točkasti keratitis, keratitis, obojenje rožnice, iscjedak iz oka, fotofobija, zamućen vid, smanjena vidna oštrina, blefarospazam, neugodan osjećaj u oku, svrbež oka, konjunktivalni folikuli, poremećaj konjunktive, osjećaj stranog tijela u oku, pojačano suzenje, eritem vjeđa, edem vjeđa, poremećaj vjeđa, okularna hiperemija
corneal erosion, eye discharge, visual disturbance, blepharitis
erozija rožnice, iscjedak iz oka, smetnje vida, blefaritis
corneal erosion, meibomianitis, conjunctival haemorrhage, eyelid margin crusting, trichiasis, distichiasis.
erozija rožnice, meibomianitis, konjunktivalna hemoragija, krustanje na rubovima vjeđa, trihijaza, distihijaza.
corneal erosion, ocular burning, allergic conjunctivitis, blepharitis, worsening of visual acuity, asthenopia, conjunctival oedema, foreign body sensation, ocular dryness, eye pain, photophobia, tearing , eye discharge, visual disturbance/blurred vision, increased iris pigmentation, eyelash darkening
erozija rožnice, pečenje oka, alergijski konjunktivitis, blefaritis, pogoršanje oštrine vida, astenopija, edem konjunktive, osjećaj stranog tijela, suhoća oka, bol u oku, fotofobija, suzenje, iscjedak iz oka, smetnje vida/zamućen vid, povećana pigmentacija šarenice, tamnjenje trepavica
corneal erosion, ocular burning, allergic conjunctivitis, blepharitis, worsening of visual acuity, eye discharge, visual disturbance, eyelash darkening
erozija rožnice, pečenje u očima, alergijski konjunktivitis, blefaritis, pogoršanje oštrine vida, iscjedak iz oka, smetnje vida, tamnjenje trepavica.
Corneal erosion, reversible and sometimes in association with aberrant eyelash growth.
Erozija rožnice, reverzibilna i ponekad udružena s aberantnim rastom trepavica.
Corneal erosion, serious* Scleromalacia*
Erozija rožnice, ozbiljna* Skleromalacija
corneal erosion, uveitis, keratitis, eye inflammation, photopsia, blepharitis, conjunctival oedema, halo vision, conjunctivitis, conjunctival follicles, hypoaesthesia eye, meibomianitis, ectropion, anterior chamber pigmentation, mydriasis, cataract, eyelid margin crusting, asthenopia
erozija rožnice, uveitis, keratitis, upala oka, fotopsija, blefaritis, konjunktivalni edem, pojava svjetlećih krugova oko izvora svjetla, konjunktivitis, konjunktivalni folikuli, hipoestezija oka, upala Meibomovih žlijezda, ektropij, pigmentacija prednje očne sobice, midrijaza, katarakta, stvaranje krusti na rubu vjeđe, astenopija
Corneal infection
infekcija rožnice
Corneal infiltrates* Corneal disorder * Corneal scar*
Infiltrati rožnice* Poremećaj rožnice* Ožiljak rožnice
corneal infiltrates, corneal staining, blurred vision, eye irritation, dry eye foreign body sensation in eyes, lacrimation increased, asthenopia, ocular hyperaemia
rožnični infiltrati, obojenje rožnice, zamućenje vida, nadražaj oka, suho oko, osjećaj stranog tijela u očima, pojačano suzenje, astenopija, hiperemija oka
corneal infiltrates, corneal staining, blurred vision, eye irritation, dry eye, foreign body sensation in eyes, lacrimation increased, asthenopia, ocular hyperaemia
rožnični infiltrati, obojenje rožnice, zamućenje vida, nadražaj oka, suho oko, osjećaj stranog tijela u očima, pojačano suzenje, astenopija, hiperemija oka
Corneal lesion*, Exophthalmos, Retinitis, Scotoma, Eye disorder (inc. eyelid) NOS, Dacryoadenitis acquired, Photophobia, Photopsia, Optic neuropathy#, Different degrees of visual impairment (up to blindness)*
Kornelane lezije*, egzoftalmus, retinitis, skotom, nespecificirani poremećaj oka (uključujući kapak), stečeni dakrioadenitis, fotofobija, fotopsija, optička neuropatija#, različiti stupnjevi oštećenja vida (do sljepoće)
Corneal limbal mononuclear cell infiltrates were noted in 1/4 male monkeys treated with 0.5 mg/ml and in 4/4 males and 1/4 females treated with 1.0 mg/ml.
Infiltrati mononuklearnih stanica u limbusu rožnice bili su prisutni u u 1/4 mužjaka koji su primali 0,5 mg/ml i u 1/4 ženki majmuna koje su primale 1,0 mg/ml.
Corneal limbal mononuclear cell infiltrates were noted in 1/4 male monkeys treated with 0.5 mg/ml and in 4/4 males and 1/4 females treated with1.0 mg/ml.
Infiltrati mononuklearnih stanica u limbusu rožnice bili su prisutni u 1/4 mužjaka koji su primali 0,5 mg/ml i u 1/4 ženki majmuna koje su primale 1,0 mg/ml.
corneal oedema, eye oedema, eye swelling, conjunctivitis, mydriasis, visual disturbance, eyelid margin crusting
edem rožnice, edem oka, oticanje oka, konjunktivitis, midrijaza, smetnje vida, stvaranje krusti na rubu vjeđe
Corneal opacities may occur during sedation (see also the section on Special precautions for the use in animals).
Za vrijeme sedacije mogu nastati zamućenja rožnice (vidjeti dio o Posebnim mjerama opreza prilikom primjene na životinjama).
Corneal perforation* Corneal ulcer*
Perforacija rožnice* Ulkus rožnice
corneal reflex decreased, lacrimation increased
oslabljeni kornealni refleks, pojačano suzenje
coronary heart disease (symptoms can include chest pain or tightness, breathlessness or choking), heart failure, high or low blood pressure
koronarnu bolest srca (simptomi mogu uključivati bol ili stezanje u prsnom košu, nedostatak zraka ili gušenje), zatajenje srca, povišeni ili sniženi krvni tlak
coronary heart disease (symptoms can include chest pain or tightness, breathlessness or choking), heart failure, low blood pressure
koronarne bolesti srca (simptomi mogu uključivati bol ili stezanje u prsnom košu, nedostatak zraka ili gušenje), srčanog zatajenja, niskog krvnog tlaka,